Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...
Sanofi: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision ...
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...
McKnight's Senior Living10h
Making a pitch to exempt healthcare from federal funding, staffing cuts
A coalition of health-related advocacy organizations is urging President Trump to include federal healthcare agencies on the list of entities exempt from cuts in staff members and research funding, ...
McKnight's Long-Term Care News11h
After struggle to regain Medicare and Medicaid certification, one of America’s largest nursing homes has 200-plus empty beds
The nation’s second-largest skilled nursing facility reopened after having its Medicare certification revoked, but vacancy is still 30%.
Watauga Democrat12h
Graystone Eye launches Chronic Care Management Program for Medicare patients
HICKORY – Graystone Eye has launched its new Chronic Care Management (CCM) program, designed to provide comprehensive support ...
Managed Healthcare Executive18h
Health Equity: Why It’s Vital to Star Ratings Performance
With the introduction of the Health Equity Index (HEI) to Star Ratings methodology, health plans have yet another incentive ...
I Am Loading Up Big Dividends For My Golden Years
Healthcare inflation outpaces CPI due to provider shortages. Find out why income investing ensures steady returns despite ...